These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 3673100)

  • 21. [Desferrioxamine treatment of osteomalacia caused by aluminum poisoning].
    Charhon SA; Chavassieux P; Chapuy MC; Accominotti M; Traeger J; Meunier PJ
    Presse Med; 1986 Jan; 15(2):55-9. PubMed ID: 2935857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clearance of aluminum by hemodialysis: effect of desferrioxamine.
    Milliner DS; Hercz G; Miller JH; Shinaberger JH; Nissenson AR; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S100-3. PubMed ID: 3457984
    [No Abstract]   [Full Text] [Related]  

  • 24. The early effects of aluminium deposition and dialysis on bone in chronic renal failure: a cross-sectional bone-histomorphometric study.
    Dahl E; Nordal KP; Halse J; Flatmark A
    Nephrol Dial Transplant; 1990; 5(6):449-56. PubMed ID: 2122323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature].
    Seidowsky A; Dupuis E; Drueke T; Dard S; Massy ZA; Canaud B
    Nephrol Ther; 2018 Feb; 14(1):35-41. PubMed ID: 29174672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Microcytic anemia in dialysis patients: reversible marker of aluminum toxicity.
    Swartz R; Dombrouski J; Burnatowska-Hledin M; Mayor G
    Am J Kidney Dis; 1987 Mar; 9(3):217-23. PubMed ID: 3826071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copper removal from renal patients using desferrioxamine chelation to reduce aluminium overload.
    Hewitt CD; Garstang FM; O'Hara M; Metcalfe PJ; Ackrill P; Day JP
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 7():431-4. PubMed ID: 3776602
    [No Abstract]   [Full Text] [Related]  

  • 29. The bone scan in patients with aluminium-associated bone disease.
    Botella J; Gallego JL; Fernandez-Fernandez J; Sanz-Guajardo D; de Miguel A; Ramos J; Franco P; Enriques R; Sanz-Moreno C
    Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():403-9. PubMed ID: 3991532
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients.
    Kausz AT; Antonsen JE; Hercz G; Pei Y; Weiss NS; Emerson S; Sherrard DJ
    Am J Kidney Dis; 1999 Oct; 34(4):688-93. PubMed ID: 10516350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnosis and treatment of aluminium overload in end-stage renal failure patients.
    Nephrol Dial Transplant; 1993; 8 Suppl 1():1-4. PubMed ID: 8389013
    [No Abstract]   [Full Text] [Related]  

  • 32. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Consensus conference. Paris, France, 27 June 1992.
    Nephrol Dial Transplant; 1993; 8 Suppl 1():1-54. PubMed ID: 8389014
    [No Abstract]   [Full Text] [Related]  

  • 34. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 35. Deferoxamine for the diagnosis and treatment of aluminum-associated osteodystrophy.
    Charhon S; el Yafi S; Gaillard M; Beruard M; Janin G; Accominotti M; Traeger J; Meunier PJ
    Contrib Nephrol; 1988; 64():160-9. PubMed ID: 3180823
    [No Abstract]   [Full Text] [Related]  

  • 36. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

  • 37. Aluminium-related osteodystrophy and desferrioxamine treatment: role of phosphorus.
    Jorgetti V; Soeiro NM; Mendes V; Pereira RC; Crivellari ME; Coutris G; Borelli A; Leite MO; Nussenzweig I; Marcondes M
    Nephrol Dial Transplant; 1994; 9(6):668-74. PubMed ID: 7970094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The chemistry of desferrioxamine chelation for aluminum overload in renal dialysis patients.
    Day JP; Ackrill P
    Ther Drug Monit; 1993 Dec; 15(6):598-601. PubMed ID: 8122301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of aluminium and magnesium effects on initiation and promotion of renal osteodystrophy in patients with chronic renal failure].
    Nakamrua M; Sato N; Tsukamoto Y; Marumo F; Iwanami S
    Nihon Jinzo Gakkai Shi; 1986 Apr; 28(4):421-8. PubMed ID: 3747253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.